Edesa Biotech, Inc. — fact timeline

Edesa Biotech, Inc. issued an aggregate of 729,241 common shares of common stock to certain investors for aggregate purchase price of approximately $3.5 million.

“Pursuant to the Purchase Agreement, the Purchasers have agreed to purchase, for an aggregate purchase price of approximately $3.5 million, an aggregate of 729,241 common shares (“Shares”), without par value, at a purchase price of $4.69 per Share for Purchasers other than the Company’s Chief Executive Officer, and $5.21 per Share for the Company’s Chief Executive Officer.”

Edesa Biotech, Inc. entered into Registration Rights Agreement with the Purchasers valued at Company agrees to file registration statement for resale of shares within 45 days after Closing (effective 2026-06-10).

“Also on June 10, 2026, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers.”

Edesa Biotech, Inc. entered into Securities Purchase Agreement with certain investors (each, a Purchaser and collectively, the Purchasers) valued at $3.5 million aggregate purchase price for 729,241 common shares at $4.69 per Share ($5.21 per Share (effective 2026-06-10).

“On June 10, 2026, Edesa Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain investors (each, a “Purchaser” and collectively, the “Purchasers”).”

Edesa Biotech, Inc. shareholders approved Appointment of MNP LLP as the Company’s Auditors and Independent Registered Public Accounting Firm for the Ensuing Year at the 2026-09-30 meeting.

“Proposal No. 4 - Appointment of MNP LLP as the Company’s Auditors and Independent Registered Public Accounting Firm for the Ensuing Year The shareholders approved the appointment of MNP LLP as the Company’s auditors and independent registered public accounting firm for the fiscal year ending September 30, 2026. For Withhold Broker Non-Votes 4,814,478 87,443 N/A”

Edesa Biotech, Inc. shareholders approved Approval of Amendment to the 2019 Equity Incentive Compensation Plan.

“Proposal No. 3 - Approval of Amendment to the 2019 Equity Incentive Compensation Plan The shareholders approved an amendment to the Company’s 2019 Plan to (i) increase the number of shares available for issuance thereunder plan by 750,000 shares and (ii) eliminate the annual per participant option grant limit. For Against Abstain Broker Non-Votes 2,613,551 130,589 10,680 2,147,101”

Edesa Biotech, Inc. shareholders approved Advisory Vote on Executive Compensation.

“Proposal No. 2 - Advisory Vote on Executive Compensation The shareholders approved, on an advisory basis, the executive compensation of the named executive officers as disclosed in the proxy statement for the Annual Meeting, by the following vote. For Against Abstain Broker Non-Votes 2,670,075 69,281 15,464 2,147,101”

Edesa Biotech, Inc. shareholders approved Election of the Company’s Directors.

“Proposal No. 1 - Election of the Company’s Directors Based upon the following votes, the shareholders elected Joan Chypyha, David Liu, Sean MacDonald, Patrick Marshall, Pardeep Nijhawan, Charles Olson and Carlo Sistilli to serve as members of the Company’s board of directors until the annual meeting of shareholders to be held in 2027 or until their successors are duly elected and qualified. For Withhold Broker Non-Votes Joan Chypyha 2,705,856 48,964 2,147,101 David Liu 2,674,286 80,534 2,147,101 Sean MacDonald 2,674,082 80,738 2,147,101 Patrick Marshall 2,706,023 48,797 2,147,101 Pardeep Nijhawan 2,705,297 49,523 2,147,101 Charles Olson 2,705,959 48,861 2,147,101 Carlo Sistilli 2,673,724 81,096 2,147,101”

Edesa Biotech, Inc. reported the six months ended March 31, 2026 results: net income a net loss of $6.5 million, or $0.78 per common share, EPS $0.78 per common share.

“For the six months ended March 31, 2026, Edesa reported a net loss of $6.5 million, or $0.78 per common share, compared to a net loss of $3.2 million, or $0.74 per common share, for the six months ended March 31, 2025.”

Edesa Biotech, Inc. reported the three months ended March 31, 2026 results: net income a net loss of $4.2 million, or $0.49 per common share, EPS $0.49 per common share.

“For the quarter ended March 31, 2026, Edesa reported a net loss of $4.2 million, or $0.49 per common share, compared to a net loss of $1.6 million, or $0.30 per common share, for the quarter ended March 31, 2025.”

Peter J. Weiler was appointed as Chief Financial Officer at Edesa Biotech, Inc..

“the Company appointed Peter J. Weiler to serve as the Company’s Chief Financial Officer, effective May 1, 2025”

Stephen Lemieux resigned as Chief Financial Officer at Edesa Biotech, Inc..

“Stephen Lemieux, Chief Financial Officer of Edesa Biotech, Inc. (the “Company”), notified the Company of his intention to resign from his position and responsibilities as Chief Financial Officer, effective May 1, 2025, to pursue another professional opportunity.”

Edesa Biotech, Inc.: Filed notice of alteration to articles to create rights, preferences and restrictions for Series B-1 Convertible Preferred Shares (effective 2025-02-12).

“On February 12, 2025, the Company filed a notice of alteration to its articles to create the rights, preferences and restrictions pertaining to the Preferred Shares.”

David Liu was appointed as Director at Edesa Biotech, Inc..

“the Company appointed David Liu, the Lead Investor Nominee, to serve on the Board of Directors”

Edesa Biotech, Inc.: Filed Amended Articles to amend rights, preferences, restrictions and other matters pertaining to the Preferred Shares (effective 2024-10-30).

“On October 30, 2024, the Company filed Amended Articles to amend the rights, preferences, restrictions and other matters pertaining to the Preferred Shares.”

Edesa Biotech, Inc. reported the six months ended March 31, 2024 results: net income $3.5 million for the six months ended March 31, 2024, EPS $1.12 per common share.

“For the six months ended March 31, 2024, Edesa reported a net loss of $3.5 million, or $1.12 per common share”

Edesa Biotech, Inc. reported the three and six months ended March 31, 2024 results: net income $1.9 million for the quarter ended March 31, 2024, EPS $0.58 per common share.

“For the quarter ended March 31, 2024, Edesa reported a net loss of $1.9 million, or $0.58 per common share”

Edesa Biotech, Inc. reported the three months ended December 31, 2023 results: net income a net loss of $1.7 million, or $0.54 per common share, EPS $0.54 per common share.

“Edesa reported a net loss of $1.7 million, or $0.54 per common share”

Edesa Biotech, Inc. reported fiscal year ended September 30, 2023 results: net income net loss of $8.4 million, EPS $2.93 per common share.

“For the year ended September 30, 2023, Edesa reported a net loss of $8.4 million, or $2.93 per common share, compared to a net loss of $17.6 million, or $8.37 per common share, for the year ended September 30, 2022.”

Edesa Biotech, Inc. entered into Credit Agreement with Pardeep Nijhawan Medicine Professional Corporation valued at $10 million (effective 2023-10-20).

“Effective October 20, 2023, the Company entered into a Credit Agreement (the “ Credit Agreement ”) with Pardeep Nijhawan Medicine Professional Corporation (the “ Lender ”), an entity controlled by Dr. Nijhawan, providing for an unsecured revolving credit facility (the “ Facility ”) in the principal amount of up to $10 million”

Edesa Biotech, Inc. entered into Multi-Year Contribution Agreement with Government of Canada valued at up to CAD $23 million ($17 million USD) (effective 2023-10-12).

“On October 12, 2023, Edesa Biotech Research, Inc. (“Edesa Biotech Research”), a wholly owned subsidiary of Edesa Biotech, Inc. (the “Company”) and the Company, as guarantor, entered into a multi-year contribution agreement (the “Agreement”) with the Government of Canada.”

Stephen Lemieux was appointed as Chief Financial Officer at Edesa Biotech, Inc..

“Edesa Biotech, Inc. (the “Company”) has appointed Stephen Lemieux (age 47) as our Chief Financial Officer pursuant to an employment agreement.”

Edesa Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 22, 2023, Edesa Biotech, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common shares, no par value per share (the “Common Shares”), for the last 30 consecutive business days, the Company is not in compliance with the minimum bid price requirement of $1.00 per share for continued listing, as set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification has no immediate impact on the listing of the Company’s Common Shares on The Nasdaq C”

Edesa Biotech, Inc. shareholders approved Appointment of MNP LLP as the Company’s Auditors and Independent Registered Public Accounting Firm for the Ensuing Year.

“Proposal No. 4 - Appointment of MNP LLP as the Company’s Auditors and Independent Registered Public Accounting Firm for the Ensuing Year Based upon the following votes, the shareholders approved the appointment of MNP LLP as the Company’s independent registered public accounting firm until the close of the 2024 annual meeting of shareholders or until a successor is appointed. For Withhold 10,225,858 528,704”

Edesa Biotech, Inc. shareholders approved Amendment to 2019 Equity Incentive Compensation Plan.

“Proposal No. 3 - Amendment to 2019 Equity Incentive Compensation Plan The shareholders approved the amendment to the Company’s 2019 Equity Incentive Compensation Plan (the “2019 Plan”) to increase the number of shares available for issuance under the 2019 Plan by 1,380,000 shares as disclosed in the Proxy Statement, by the following vote. For Against Abstain Broker Non-Votes 6,490,800 530,086 399,667 3,334,009”

Edesa Biotech, Inc. shareholders approved Advisory Vote on Executive Compensation.

“Proposal No. 2 - Advisory Vote on Executive Compensation The shareholders approved, on an advisory basis, the executive compensation of the named executive officers as disclosed in the Proxy Statement, by the following vote. For Against Abstain Broker Non-Votes 6,549,767 550,638 320,148 3,334,009”

Edesa Biotech, Inc. shareholders approved Election of the Company’s Directors.

“Proposal No. 1 – Election of the Company’s Directors Based upon the following votes, the shareholders elected Joan Chypyha, Sean MacDonald, Patrick Marshall, Pardeep Nijhawan, Frank Oakes, Charles V. Olson and Carlo Sistilli to serve as members of the Company’s board of directors until the annual general meeting of shareholders to be held in 2024 or until their successors are duly elected and qualified. For Withhold Broker Non-Votes Joan Chypyha 7,116,425 304,128 3,334,009 Sean MacDonald 7,260,834 159,719 3,334,009 Patrick Marshall 7,116,744 303,809 3,334,009 Pardeep Nijhawan, MD 7,058,239 362,314 3,334,009 Frank Oakes 7,064,233 356,320 3,334,009 Charles Olson, D.Sc. 7,116,984 303,569 3,334,009 Carlo Sistilli, CPA, CMA 7,116,801 253,752 3,334,009”

Kathi Niffenegger departed as Chief Financial Officer at Edesa Biotech, Inc..

“On May 23, 2023, Kathi Niffenegger, the Chief Financial Officer of the Company, notified the Company of her intention to retire from her position and responsibilities as Chief Financial Officer effective July 15, 2023.”

Edesa Biotech, Inc. reported six months ended March 31, 2023 results: net income net loss of $4.67 million, EPS $0.24 per common share.

“For the six months ended March 31, 2023, Edesa reported a net loss of $4.67 million, or $0.24 per common share, compared to a net loss of $8.95 million, or $0.66 per common share, for the six months ended March 31, 2022.”

Edesa Biotech, Inc. reported quarter ended March 31, 2023 results: net income net loss of $2.33 million, EPS $0.12 per common share.

“For the quarter ended March 31, 2023, Edesa reported a net loss of $2.33 million, or $0.12 per common share, compared to a net loss of $4.57 million, or $0.33 per common share, for the quarter ended March 31, 2022.”

Edesa Biotech, Inc. entered into Equity Distribution Agreement with Canaccord Genuity LLC valued at up to $20.0 million (effective 2023-03-27).

“On March 27, 2023 Edesa Biotech, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Canaccord Genuity LLC (“Canaccord”), pursuant to which the Company may offer and sell from time to time, through Canaccord as sales agent and/or principal, common shares of the Company, no par value per share (the “Common Shares”), having an aggregate offering price of up to $20.0 million.”

Edesa Biotech, Inc. reported the three months ended December 31, 2022 results: net income a net loss of $2.33 million, or $0.13 per common share, EPS $0.13 per common share.

“For the quarter ended December 31, 2022, Edesa reported a net loss of $2.33 million, or $0.13 per common share”

Edesa Biotech, Inc. reported fiscal year ended September 30, 2022 results: net income $17.55 million, or $1.05 per common share, EPS $1.05 per common share.

“For the fiscal year ended September 30, 2022, Edesa reported a net loss of $17.55 million, or $1.05 per common share, compared to a net loss of $13.34 million, or $1.10 per common share, for the fiscal year ended September 30, 2021.”

Edesa Biotech, Inc. entered into Subscription Agreements with certain non-U.S. investors and certain United States resident investors valued at aggregate of 2,691,337 common shares, Class A Warrants for 1,345,665 shares, Class B Warrants for 1, (effective 2022-11-02).

“On November 2, 2022, Edesa Biotech, Inc. (the “Company”) entered into Subscription Agreements with certain non-U.S. investors ( the “Non-U.S. Subscription Agreements”) and Subscription Agreements with certain United States resident investors (the “U.S. Subscription Agreements” and together with the Non-U.S. Subscription Agreements, the “Subscription Agreements”) providing for the issuance and sale by the Company of an aggregate of 2,691,337 (the “Shares”) of the Company’s common shares, no par value (the “Common Shares”), (ii) Class A Warrants to purchase up to an aggregate of 1,345,665 Common Shares (the “Class A Warrants”) and (iii) Class B Warrants to purchase up to an aggregate of 1,345,665 Common Shares (the “Class B Warrants”, and together with the Class A Warrants, the “Warrants”).”

Jennifer Chao was appointed as Director at Edesa Biotech, Inc..

“the Board voted to appoint Jennifer Chao as a director of the Company to fill a vacancy on the Board”

Peter van der Velden resigned as Director at Edesa Biotech, Inc..

“On February 28, 2022, Peter van der Velden notified the Board of Directors (the “Board”) of Edesa Biotech, Inc. (the “Company”) of his decision to resign from the Board and its committees, effective as of February 28, 2022.”